Arkadios Wealth Advisors Buys 6,734 Shares of GSK PLC Sponsored ADR $GSK

Arkadios Wealth Advisors increased its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 10.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,760 shares of the pharmaceutical company’s stock after buying an additional 6,734 shares during the period. Arkadios Wealth Advisors’ holdings in GSK were worth $2,640,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in GSK. Ethic Inc. lifted its holdings in shares of GSK by 13.1% during the second quarter. Ethic Inc. now owns 159,588 shares of the pharmaceutical company’s stock valued at $6,157,000 after purchasing an additional 18,499 shares during the last quarter. Cullen Frost Bankers Inc. lifted its holdings in shares of GSK by 4.7% during the second quarter. Cullen Frost Bankers Inc. now owns 375,481 shares of the pharmaceutical company’s stock valued at $14,418,000 after purchasing an additional 16,999 shares during the last quarter. Yousif Capital Management LLC lifted its holdings in shares of GSK by 7.9% during the second quarter. Yousif Capital Management LLC now owns 25,681 shares of the pharmaceutical company’s stock valued at $986,000 after purchasing an additional 1,875 shares during the last quarter. Trust Co. of Toledo NA OH lifted its holdings in shares of GSK by 2.7% during the second quarter. Trust Co. of Toledo NA OH now owns 30,805 shares of the pharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 797 shares during the last quarter. Finally, NBT Bank N A NY lifted its holdings in shares of GSK by 3.2% during the second quarter. NBT Bank N A NY now owns 14,765 shares of the pharmaceutical company’s stock valued at $567,000 after purchasing an additional 452 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Price Performance

Shares of GSK opened at $47.06 on Friday. The company has a market capitalization of $95.66 billion, a P/E ratio of 13.29, a price-to-earnings-growth ratio of 1.90 and a beta of 0.53. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The firm has a 50 day moving average of $41.96 and a 200 day moving average of $39.64. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $47.16.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.22. The company had revenue of $11.35 billion during the quarter, compared to the consensus estimate of $8.21 billion. GSK had a net margin of 17.16% and a return on equity of 51.07%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.50 earnings per share. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. As a group, equities research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 8th. Shareholders of record on Friday, November 14th will be given a $0.4171 dividend. This represents a $1.67 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date of this dividend is Friday, November 14th. GSK’s payout ratio is 47.74%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on GSK shares. Cfra set a $53.00 target price on shares of GSK in a report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of GSK in a report on Wednesday, October 8th. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a report on Monday. Finally, Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, September 5th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $42.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.